Zim Laboratories' Q2 FY 2026-27 Quarterly Results
- 05 Nov 2026
Result Summary
- Zim Laboratories Ltd reported a 13.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 18.7%.
- Its expenses for the quarter were up by 9.7% QoQ and 21.3% YoY.
- The net profit decreased 49.0% QoQ and increased 388.1% YoY.
- The earnings per share (EPS) of Zim Laboratories Ltd declined at 0.38 during Q2 FY 2026-27.
Financial Statments for Q2 FY 2026-27
(₹ crores) | Q2FY27 | Q1FY27 | Q2FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 107.75 | 95.17 | 90.75 | 13.2% | 18.7% |
Total Expenses | 110.49 | 100.74 | 91.10 | 9.7% | 21.3% |
Profit Before Tax | -2.74 | -5.57 | -0.34 | -50.8% | 705.9% |
Tax | -0.69 | -1.56 | 0.08 | -55.8% | -962.5% |
Profit After Tax | -2.05 | -4.02 | -0.42 | -49.0% | 388.1% |
Earnings Per Share | -0.38 | -0.75 | -0.09 | -49.3% | 322.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Zim Laboratories Ltd operates in the pharmaceutical industry, specializing in the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company is known for its focus on novel drug delivery solutions, which include oral thin films, multi-particulate systems, and sustained-release formulations. As of the latest information available by October 2023, Zim Laboratories has not reported any major developments or changes in its business strategy. The company continues to focus on enhancing its product portfolio and expanding its market presence, both domestically and internationally. However, specific recent developments or strategic initiatives are not available in the provided data.
Revenue
In the second quarter of fiscal year 2027 (Q2FY27), Zim Laboratories Ltd reported a total income of ₹107.75 crores. This represents a 13.2% increase from the previous quarter (Q1FY27), where the total income was ₹95.17 crores. When compared to the same quarter in the previous fiscal year (Q2FY26), the total income increased by 18.7%, up from ₹90.75 crores. The growth in revenue over both the quarter and the year demonstrates a positive trend in the company's ability to generate income. The company has shown consistent revenue growth, which is a critical factor in its overall financial performance.
Profitability
During Q2FY27, Zim Laboratories Ltd reported a loss before tax of ₹2.74 crores, which is an improvement from a loss of ₹5.57 crores in the previous quarter. Compared to Q2FY26, where the loss before tax was ₹0.34 crores, there has been a significant increase in losses. The tax expense for Q2FY27 was recorded at a negative ₹0.69 crores, indicating a tax credit situation, compared to a negative ₹1.56 crores in Q1FY27 and a tax expense of ₹0.08 crores in Q2FY26. The profit after tax (PAT) for Q2FY27 was a loss of ₹2.05 crores, showing a reduction in losses from the previous quarter's PAT loss of ₹4.02 crores. Compared to the same quarter last year, where the loss amounted to ₹0.42 crores, the profitability has significantly decreased. Earnings per share (EPS) also saw an improvement, with a reported loss of ₹0.38 in Q2FY27, compared to a loss of ₹0.75 in Q1FY27. The EPS in Q2FY26 was a loss of ₹0.09, indicating a year-over-year decline.
Operating Metrics
The operating metrics of Zim Laboratories Ltd for Q2FY27 reflect a continued focus on managing expenses and mitigating losses. Total expenses for the quarter were ₹110.49 crores, marking a 9.7% increase from Q1FY27, where expenses totaled ₹100.74 crores. Year-over-year, the expenses have risen by 21.3% from ₹91.10 crores in Q2FY26. This increase in expenses outpaced the growth in total income, impacting the company's profitability in the quarterly and yearly comparisons. The QoQ reduction in loss before tax and profit after tax suggests some operational adjustments that have slightly improved the financial outcome compared to the previous quarter. However, the YoY comparison indicates a need for further evaluation of cost management strategies. Earnings per share, as a key indicator, improved on a quarterly basis but declined year-over-year, reflecting the challenges in maintaining profitability amidst rising operational costs.
FAQs
Zim Laboratories Ltd announced its Q2 FY 2026-27 results on 5 November, 2026.
Zim Laboratories Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Zim Laboratories Ltd Q2 FY 2026-27 results include:
- Revenue: ₹107.75 crore
- Net Profit: ₹-2.05 crore
- EBITDA: ₹7.73 crore
- Year-over-Year Growth: 18.7%
- Quarter-over-Quarter Growth: 13.2%
Zim Laboratories Ltd reported a net loss of ₹-2.05 crore in Q2 FY 2026-27, reflecting a 388.1% year-over-year growth.
Zim Laboratories Ltd posted a revenue of ₹107.75 crore in Q2 FY 2026-27.